---
layout: default
title: Titanium Dioxide
parent: Model Prediction Only (L5)
nav_order: 911
evidence_level: L5
indication_count: 10
---

# Titanium Dioxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Titanium Dioxide: From Pigment and UV Filter to Drug-Induced Osteoporosis

## One-Sentence Summary

Titanium dioxide is mainly used as a pigment, UV filter and excipient, and it appears in many sunscreen and foundation products on the Canadian market.
The TxGNN model predicts it may be effective for **drug-induced osteoporosis**,
but **0 clinical trials** and **0 publications** currently support this prediction, so it rests on model output alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Use | Pigment, UV filter and excipient (no formal approved indication text on file) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, titanium dioxide is an inert pigment, UV filter and excipient rather than a drug with a defined therapeutic target. No known mechanism links it to bone metabolism or to osteoporosis caused by medications.

The very high TxGNN score (about 99.9998%) is a knowledge-graph prediction. It is not backed by trials, literature or a documented biological rationale. Scores this high are common in the model's output and do not by themselves indicate real efficacy.

Other predictions for this drug are also weakly supported:
- **Diabetic retinopathy** (rank 2) has five retrieved papers, but none shows TiO2 treating or preventing the disease. They cover analytical methods, an eye phantom, an imaging-agent study and a general nanoparticle review. At most they suggest a diagnostic or nanomedicine relevance.
- **Cataract-related predictions** (ranks 3 to 10) have no trials or literature. Several share an identical score, which suggests a shared knowledge-graph neighborhood effect.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

20 licenses are on record. The five main ones are listed below; none has approved indication text or dosage form data on file.

| DIN | Product Name |
|---------|------|
| 2538482 | WEIGHTLESS SKIN FOUNDATION SPF 15 |
| 2406926 | MARCELLE CC CREAM / CRÈME COMPLETE CORRECTION SPF 35 |
| 2434016 | TEINT LUMIÈRE |
| 2529130 | FLUID SPF 15 |
| 2492970 | SUPERDEFENSE CITY BLOCK DAILY ENERGY + FACE PROTECTOR SPF 50 |

These are topical sun-protection and cosmetic-type products. They give no support for a systemic bone indication.

---

## Safety Considerations

Please refer to the package insert for safety information. No drug-drug interactions were found in the queried data.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on a model score alone (Evidence Level L5). There are no clinical trials, no supporting literature and no plausible mechanism. The marketed products are topical sun-protection and cosmetic products, which do not match a systemic bone indication.

**To proceed, the following is needed:**
- Mechanism of action data and a plausible biological rationale linking TiO2 to bone metabolism
- Preclinical studies (for example, bone-loss models) showing a therapeutic effect
- Route and formulation compatibility assessment, since current products are topical and osteoporosis therapy is typically systemic
- Health Canada package insert warnings and contraindications for a safety screen
- A reassessment of the diabetic retinopathy prediction only if direct therapeutic evidence emerges

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

